Seeing the patient and carer behind the many faces of ill-health #multimorbidity @JLAageing @OfficialNIHR @EngageFMS

Last week I attended a National Institute for Health Research (NIHR) workshop on older people with complex needs.  The more common term used in medical and scientific circles for 'complex needs' is 'multi-morbidity.'  Which means suffering from two or more conditions at the same time. But I prefer the former term. As statistics from the Office... Continue Reading →

Government pushes forward with review to speed up availability of innovative medicines and treatments

Two posts in one day!  Ah, those were the days when we got two Post Office deliveries a day.... Just to say the Government has published the full terms of reference for its Innovative Medicines and MedTech Review to be headed up by Sir Hugh Taylor who is currently Chair of Guy's and St Thomas's.  Yes, that's... Continue Reading →

Blog: We have the public to thank for this week’s well-informed decisions in health research

We have had two pieces of good news about health research of patient benefit this week. First, the National Institute for Health and Care Excellence (NICE) issued new guidance saying that tamoxifen or raloxifene taken daily for five years can cut breast cancer risk by 40%.  This means women at risk of developing breast cancer have... Continue Reading →

NICE announcement on anti-TNF therapy

Today's guidelines by the National Institute for Health and Clinical Excellence (NICE) to widen access to anti-TNF drugs for the treatment of rheumatoid arthritis has been widely welcomed by patient groups and medical research charities such as Arthritis Research UK. Those digging further into the story may be interested to know that it was researchers... Continue Reading →

Time to open up about industry

Every so often a story and resulting furore crops up in the media about charities, patient groups and their closeneness to industry and, in particular, pharmaceutical companies.   Journalists and the public will quite rightly ask: is it in the public interest?  I can well remember my first encounter with big pharma in my early days... Continue Reading →

Blog at WordPress.com.

Up ↑

%d bloggers like this: